- Conditions
- Pneumonia, Pneumococcal
- Interventions
- V116, PCV15, PPSV23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 717 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1273–1296
of 7,390
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Alkylating Agent-Related Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Lenalidomide, Cytarabine, Idarubicin, Pharmacological Study, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- High Grade Glioma, Glioblastoma
- Interventions
- BDTX-1535, BDTX-1535 combined with radiation therapy, BDTX-1535 combined with temozolomide and radiation therapy
- Drug
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Phoenix, Arizona
- Conditions
- Melanoma (Skin), Melanoma
- Interventions
- Pembrolizumab, EDP1503
- Drug · Biological
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Volunteer
- Interventions
- BIIB091, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Bioavailability, Bioequivalence
- Interventions
- TEPEZZA, EDP
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Recurrent Melanoma
- Interventions
- selinexor, Correlative studies
- Drug · Other
- Lead sponsor
- Kari Kendra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
- Conditions
- Breast Cancer
- Interventions
- GRN163L
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Harvey, Illinois • Indianapolis, Indiana
- Conditions
- Cancer
- Interventions
- GSK2118436 75 mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
- Conditions
- Brain and Nervous System, Eye and Orbit
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Brookline, Massachusetts • Chapel Hill, North Carolina • Charlotte, North Carolina + 1 more
- Conditions
- Solid Tumor
- Interventions
- 7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect
- Drug
- Lead sponsor
- 7 Hills Pharma, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Breast Cancer Metastatic
- Interventions
- Paclitaxel, Pelareorep, Avelumab
- Drug · Biological
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Miami, Florida • Urbana, Illinois • Indianapolis, Indiana + 13 more
- Conditions
- Metastatic Melanoma
- Interventions
- vemurafenib + HD IL-2
- Drug
- Lead sponsor
- Clinigen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 18 more
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
- Interventions
- PF-07284890, Binimetinib, Midazolam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 39
- States / cities
- Duarte, California • San Francisco, California • Orlando, Florida + 23 more
- Conditions
- Ulcerative Colitis
- Interventions
- AVX 470, Placebo
- Drug
- Lead sponsor
- Avaxia Biologics, Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 9
- States / cities
- Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
- Conditions
- Limb-Girdle Muscular Dystrophy, Type 2E
- Interventions
- SRP-9003
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 15 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Solid Tumors
- Interventions
- Navlimetostat, Daraxonrasib, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel, Cisplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 16
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
- Interventions
- Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
- Drug · Biological · Other + 2 more
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Oklahoma City, Oklahoma
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Acinar Cell Carcinoma
- Interventions
- Olaparib, ECG, CT CAP, Tumor Biopsy
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
- Interventions
- Fosciclopirox, Fosciclopirox + Cytarabine
- Drug
- Lead sponsor
- CicloMed LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Baltimore, Maryland
- Conditions
- Lung Cancer
- Interventions
- everolimus, gefitinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York